Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABAT | P80404 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19860333 | 1.00 | ABAT (0.46) | ABATCYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL15466878 | 1.00 | ABAT (0.46) | ABATCYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL1848855 | 1.00 | ABAT (0.46) | ABATCYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL20201900 | 1.00 | ABAT (0.46) | ABATCYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL14791315 | 1.00 | ABAT (0.46) | ABATCYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL698731 | 1.00 | ABAT (0.46) | ABATCYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL698234 | 0.78 | ABAT (0.33) | ABAT | |
| SCHEMBL375674 | 0.78 | — | — | |
| SCHEMBL14211851 | 0.74 | — | — | |
| SCHEMBL15466503 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119053596-A | Heterocyclic compounds as kinase inhibitors, compositions and methods of use | 捷思英达控股有限公司 | 2024-11-29 | — | — | CN | disclosed |
| WO-2023216237-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS, AND METHODS OF USE THEREOF | JS INNOMED HOLDINGS LTD. (KY) | 2023-11-16 | — | — | WO | disclosed |
| CN-114127080-B | Heterocyclic compounds as kinase inhibitors, compositions comprising the same, and methods of use thereof | 捷思英达医药技术（上海）有限公司 | 2023-05-05 | — | — | CN | disclosed |
| US-20220220128-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2022-07-14 | — | — | US | disclosed |
| EP-3980425-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS InnoPharm (Shanghai) Ltd. (CN) | 2022-04-13 | — | — | EP | disclosed |
| US-11111246-B2 | Pharmaceutical salts of substituted-quinoxaline-type bridged-piperidine compounds | PURDUE PHARMA L.P. (US) | 2021-09-07 | — | — | US | disclosed |
| EP-3349752-B1 | AZA-ADAMANTANE COMPOUND FOR WOUND HEALING | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2021-06-30 | — | — | EP | disclosed |
| US-20200223847-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA LP (US) | 2020-07-16 | — | — | US | disclosed |
| EP-3564240-A1 | PIPERIDINE INTERMEDIATES | Purdue Pharma L.P. (US) | 2019-11-06 | — | — | EP | disclosed |
| US-10328063-B2 | Method of wound healing | CONNEXIOS LIFE SCIENCES PVT LTD (IN) | 2019-06-25 | — | — | US | disclosed |
| US-20120053348-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2423212-A1 | PROCESS FOR PRODUCTION OF 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20110178090-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2011-07-21 | — | — | US | disclosed |
| EP-2324013-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma LP (US) | 2011-05-25 | — | — | EP | disclosed |
| US-20100311977-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | PURDUE PHARMA L.P. (US) | 2010-08-26 | — | — | US | disclosed |
| EP-2221306-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | Nissan Chemical Industries, Ltd. (JP) | 2010-08-25 | — | — | EP | disclosed |
| WO-2010010458-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20050267150-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | THOMPSON RICHARD C | 2005-12-01 | — | — | US | disclosed |
| US-20050192265-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | THOMPSON RICHARD C (US) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10328063-B2 | Method of wound healing | MMP8, MMP1, UNG | ABAT 2153/4885CYP1A2 1430/4885CYP2D6 2322/4885 |
| US-20100311977-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE | CYP21A2, CYP51A1, CYP19A1 | ABAT 178/4885CYP1A2 8/4885CYP2D6 25/4885 |
| US-20050267150-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | ABAT 533/4885CYP1A2 3219/4885CYP2D6 3369/4885 |
| US-20100216726-A1 | Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof | P2RX4, P2RX5, P2RX3 | ABAT 1241/4885CYP1A2 950/4885CYP2D6 504/4885 |
| US-11111246-B2 | Pharmaceutical salts of substituted-quinoxaline-type bridged-piperidine compounds | QDPR, P2RX4, P2RX5 | ABAT 1926/4885CYP1A2 666/4885CYP2D6 224/4885 |
| US-20200223847-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | P2RX4, OPRK1, QDPR | ABAT 1457/4885CYP1A2 979/4885CYP2D6 658/4885 |
| US-20110178090-A1 | SUBSTITUTED-QUINOXALINE-TYPE BRIDGED-PIPERIDINE COMPOUNDS AND THE USES THEREOF | OPRK1, OPRD1, P2RX4 | ABAT 1846/4885CYP1A2 241/4885CYP2D6 240/4885 |
| US-20050192265-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | ABAT 533/4885CYP1A2 3219/4885CYP2D6 3369/4885 |
| US-20220220128-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | RET, BRAF, ROR1 | ABAT 3210/4885CYP1A2 4764/4885CYP2D6 4351/4885 |
| US-20120053348-A1 | METHOD FOR PRODUCING 2-AZAADAMANTANE COMPOUND FROM BICYCLOCARBAMATE COMPOUND | CNKSR1, HDAC11, HDAC1 | ABAT 262/4885CYP1A2 148/4885CYP2D6 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.